Da	te:2023.	3.13				
Yo	ur Name: Dianbao Zh	ang				
Ma	Manuscript Title:_Dysregulated expression of microRNA involved in resistance to osimertinib in EGFR mutant non-small					
	I lung cancer cells	•				
	anuscript number (if known)) :				
			II relationships/activities/interests listed below that are	e		
	-	_	eans any relation with for-profit or not-for-profit third			
			of the manuscript. Disclosure represents a commitmen	t		
to	transparency and does not	necessarily indicate a bias	s. If you are in doubt about whether to list a			
rel	ationship/activity/interest,	it is preferable that you d	o so.			
		to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>			
ma	anuscript only.					
TI.		: ::::::::::::::::::::::::::::::::::::	defined by a division of the second state of t	_•		
	• •	-	e <u>defined broadly</u> . For example, if your manuscript pert			
		• •	e all relationships with manufacturers of antihypertens	ive		
me	edication, even if that medic	cation is not mentioned in	the manuscript.			
In	itam #1 halow raport all su	nnort for the work report	ed in this manuscript without time limit. For all other in	toms		
	e time frame for disclosure i	• •	ed in this manuscript without time innit. For an other i	terris,		
LIII	e time frame for disclosure i	s the past 50 months.				
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as				
		needed)				
		Time frame: Since the initi	al planning of the work			
L	All support for the present	None				
	manuscript (e.g., funding,					
	provision of study materials, medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time frame: pas	t 36 months			
)	Grants or contracts from	None				
	any entity (if not indicated					
	in item #1 above).					

3

4

5

Royalties or licenses

Payment or honoraria for

Consulting fees

None

None

None

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
•			
9	Participation on a Data	None	
	Safety Monitoring Board or		
40	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
	ase summarize the above o	onflict of interest in the fo	llowing box:
	No conflict of interest		
Ple	ase place an "X" next to the	following statement to in	dicate your agreement:

riease place an 'A' next to the following statement to indicate your agreement:

Dat	te:	2023.3.13	
	ur Name: Yukun		
Ma cel	nuscript Title:_Dysre	gulated expression of microf	RNA involved in resistance to osimertinib in EGFR mutant non-smal
In t rela par to t	ated to the content or rties whose interests transparency and doe	arency, we ask you to disclos f your manuscript. "Related" may be affected by the conto	se all relationships/activities/interests listed below that are means any relation with for-profit or not-for-profit third ent of the manuscript. Disclosure represents a commitment bias. If you are in doubt about whether to list a bu do so.
	e following questions inuscript only.	apply to the author's relatio	onships/activities/interests as they relate to the current
to t	the epidemiology of h		d be <u>defined broadly</u> . For example, if your manuscript pertains clare all relationships with manufacturers of antihypertensive d in the manuscript.
	•	all support for the work reposure is the past 36 months.	orted in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		-	nitial planning of the work
	All support for the pres manuscript (e.g., fundi provision of study mate medical writing, article processing charges, etc No time limit for this in	None None ng, erials,	
		Time frame:	past 36 months
-	Grants or contracts fro any entity (if not indicating in item #1 above).	m None	

Royalties or licenses

Payment or honoraria for

Consulting fees

None

None

None

3

4

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	3		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	occon or occon options		
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
13	financial interests	None	
	illialiciai liiterests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	No conflict of interest		
	No conflict of interest		
-			
Ple	ease place an "X" next to the	following statement to in	dicate vour agreement:

Dat	:e:2023.	3.13		
	ur Name:Yixin Kang			
Ма	nuscript Title:_Dysregulate	d expression of microRNA	A involved in resistance to osimertinib in EGFR mutant	 non-small
cell	lung cancer cells			
Ma	nuscript number (if known):		_
In t	he interest of transparency	, we ask you to disclose a	II relationships/activities/interests listed below that ar	re
			eans any relation with for-profit or not-for-profit third	
•	•	•	of the manuscript. Disclosure represents a commitmen	nt
	-	•	. If you are in doubt about whether to list a	
rela	ationship/activity/interest,	it is preferable that you o	0 SO.	
The	following questions apply	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>	
	nuscript only.	to the dutilor 3 relations	inpopulation interests us they relate to the current	
The	author's relationships/act	ivities/interests should be	e <u>defined broadly</u> . For example, if your manuscript per	tains
			e all relationships with manufacturers of antihyperten	sive
me	dication, even if that medic	cation is not mentioned in	the manuscript.	
	· · · · · ·		ed in this manuscript without time limit. For all other	items,
the	time frame for disclosure i	s the past 36 months.		
		Name all entities with	Specifications/Comments	1
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed) Time frame: Since the initi	al planning of the work	-
	All support for the present	None	ai planning of the work	1
-	manuscript (e.g., funding,	None		-
	provision of study materials,			-
	medical writing, article			
	processing charges, etc.)			1
	No time limit for this item.			
		T:	125 manths	
,	Grants or contracts from	Time frame: pas	at 36 months	
-	any entity (if not indicated	None		1
	in item #1 above).			1

Royalties or licenses

Payment or honoraria for

Consulting fees

None

None

None

3

4

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	3		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	occon or occon options		
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
13	financial interests	None	
	illialiciai liiterests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	No conflict of interest		
	No conflict of interest		
-			
Ple	ease place an "X" next to the	following statement to in	dicate vour agreement:

Dat	e:2023	.3.13		_
	ır Name:Dongjie Xie			
Ma	nuscript Title:_Dysregulate	ed expression of microRNA	A involved in resistance to osimertinib in EGFR mutant	non-smal
cell	lung cancer cells			
Ma	nuscript number (if known	n):		_
			III relationships/activities/interests listed below that a	re
	-	-	eans any relation with for-profit or not-for-profit third	
•	•	•	of the manuscript. Disclosure represents a commitme	nt
	ransparency and does not itionship/activity/interest,	•	s. If you are in doubt about whether to list a	
reia	itionship/activity/interest,	, it is preferable that you t	10 50.	
The	following questions apply	to the author's relationsl	nips/activities/interests as they relate to the <u>current</u>	
	nuscript only.	, to the addition of chations.	inpo, activities, interests as they relate to the <u>carrent</u>	
The	author's relationships/ac	tivities/interests should be	e <u>defined broadly</u> . For example, if your manuscript per	tains
to t	he epidemiology of hypert	tension, you should declar	e all relationships with manufacturers of antihyperten	sive
me	dication, even if that medi	cation is not mentioned in	the manuscript.	
			ed in this manuscript without time limit. For all other	items,
the	time frame for disclosure	is the past 36 months.		
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed) Time frame: Since the initi	al planning of the work	
	All accompant for the propert		al planning of the work	
	All support for the present manuscript (e.g., funding,	None		
	provision of study materials,			
	medical writing, article			
processing charges, etc.)				
	No time limit for this item.			
		Time frame: pas	st 36 months	
	Grants or contracts from	None		
	any entity (if not indicated			1
	in item #1 above).			1

Royalties or licenses

Payment or honoraria for

Consulting fees

None

None

None

3

4

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	3		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	occon or occon options		
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
13	financial interests	None	
	illialiciai liiterests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	No conflict of interest		
	No conflict of interest		
-			
Ple	ease place an "X" next to the	following statement to in	dicate vour agreement:

Da	te:2023.	3.13		
	ur Name:Xianfen Zha			
Ma	anuscript Title:_Dysregulate	d expression of microRNA	involved in resistance to osimertinib in EGFR mutant no	on-small
cel	Il lung cancer cells	•		
Ma	anuscript number (if known)	:		
In	the interest of transparency	, we ask you to disclose a	II relationships/activities/interests listed below that are	
rel	ated to the content of your	manuscript. "Related" me	eans any relation with for-profit or not-for-profit third	
pa	rties whose interests may be	e affected by the content	of the manuscript. Disclosure represents a commitment	;
	-	•	. If you are in doubt about whether to list a	
rel	ationship/activity/interest,	it is preferable that you d	o so.	
		to the author's relationsh	ips/activities/interests as they relate to the current	
ma	anuscript only.			
Th	a author's relationships/act	ivities/interests should be	e <u>defined broadly</u> . For example, if your manuscript perta	inc
			e all relationships with manufacturers of antihypertensi	
	edication, even if that medic	· •	•	VC
	carcation, even in that means	action is not inclinioned in	the manascript.	
In	item #1 below, report all su	pport for the work report	ed in this manuscript without time limit. For all other it	ems.
	e time frame for disclosure i	• •		·····,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as needed)		
		Time frame: Since the initia	al planning of the work	
1	All support for the present	None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	t 36 months	
2	Grants or contracts from	None		
	any entity (if not indicated			
	in item #1 above).			

Royalties or licenses

Payment or honoraria for

Consulting fees

None

None

None

3

4

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	3		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	occon or occon options		
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
13	financial interests	None	
	illialiciai liiterests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	No conflict of interest		
	No conflict of interest		
-			
Ple	ease place an "X" next to the	following statement to in	dicate vour agreement:

Dat	re: 202	23.3.13		
		ao		-
Ma cell	nuscript Title:_Dysregula	ted expression of microRNA	A involved in resistance to osimertinib in EGFR mutant	 non-small
	nuscript number (if knov			_
	_		all relationships/activities/interests listed below that a	re
		-	eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitme	mt
-	-		s. If you are in doubt about whether to list a	III.
		st, it is preferable that you		
	,,,,	, ,		
	e following questions app nuscript only.	ly to the author's relations	hips/activities/interests as they relate to the <u>current</u>	
to t	he epidemiology of hype		e <u>defined broadly</u> . For example, if your manuscript per re all relationships with manufacturers of antihyperten n the manuscript.	
	tem #1 below, report all time frame for disclosur	• •	ted in this manuscript without time limit. For all other	items,
		Name all entities with	Specifications/Comments	1
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed) Time frame: Since the init	ial planning of the work	
	All support for the present		an planning of the work	
	manuscript (e.g., funding,	None		
	provision of study material	S,		
	medical writing, article			1
	processing charges, etc.)			
	No time limit for this item.			
		T ' f	sh 26 maniba	
,	Grants or contracts from	Time frame: pa	st so months	
-	any entity (if not indicated	NOTIC		
	in item #1 above).			

Royalties or licenses

Payment or honoraria for

Consulting fees

None

None

None

3

4

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	3		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	occon or occon options		
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
13	financial interests	None	
	illialiciai liiterests		
Ple	ease summarize the above co	onflict of interest in the fo	llowing box:
	No conflict of interest		
	No conflict of interest		
-			
Ple	ease place an "X" next to the	following statement to in	dicate vour agreement: